Galimedix Achieves Phase 1 Milestone for Oral GAL-101 in Alzheimer's Disease Development
Key Insights
Galimedix Therapeutics (search) successfully completed Phase 1 trials for oral GAL-101, triggering an undisclosed milestone payment from partner Théa Open Innovation (search).
The oral formulation demonstrated excellent safety, tolerability, and pharmacokinetic profile with effective blood-brain barrier penetration, supporting Phase 2 advancement in Alzheimer's disease (search).
GAL-101 targets misfolded amyloid beta (search) monomers to prevent toxic oligomer formation, addressing a validated target in neurodegenerative diseases affecting both brain and retina.
Galimedix Therapeutics (search) has achieved a significant clinical milestone with the successful completion of Phase 1 trials for oral GAL-101, earning an undisclosed milestone payment from its ophthalmology partner Théa Open Innovation (search). The achievement marks a crucial step forward for the novel amyloid beta (search)-targeting therapy as it advances toward Phase 2 development in Alzheimer's disease (search) and other neurological indications.
Phase 1 Results Support Alzheimer's Development
The Phase 1 trial results demonstrated that oral GAL-101 was well tolerated and clinically safe, with an excellent pharmacokinetic profile that effectively crosses the blood-brain barrier. These findings strongly support advancing the oral formulation into Phase 2 development for Alzheimer's disease (search) and other indications, according to the company announcement.
"We are gratified to have the strong support of Théa Open Innovation (search) in developing GAL-101 and excited to see such solid results in the Phase 1 trial," said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman of Galimedix Therapeutics (search). "Importantly, this milestone payment provides Galimedix with significant operational runway and will allow us to advance our development plans for GAL-101 in Alzheimer's disease (search) and other supportive R&D work."
Novel Mechanism Targets Amyloid Beta Aggregation
GAL-101 represents a small molecule approach to targeting misfolded amyloid beta (search) (Aβ) monomers, preventing the formation of toxic Aβ oligomers and protofibrils. This mechanism addresses what many studies have indicated as a major underlying cause of neurodegenerative diseases affecting both the brain and retina. The validation of anti-Aβ drugs through recent approvals has further established amyloid beta as a key target in Alzheimer's disease (search) treatment.
In preclinical testing, GAL-101 demonstrated the ability to prevent and eliminate all forms of toxic Aβ species while preserving healthy Aβ forms. The compound showed potential for neuroprotection and symptomatic alleviation in preclinical Alzheimer's disease (search) models. Notably, the oral formulation exhibited no antibody-specific immunological side effects such as ARIA (amyloid-related imaging abnormalities), very low systemic toxicity, robust storage stability, and cost-effective manufacturing characteristics.
Dual Development Strategy Across Indications
While the oral formulation advances toward Alzheimer's disease (search) trials, GAL-101's eye drop formulation is currently progressing through Phase 2 development for geographic atrophy (search), a severe form of dry age-related macular degeneration (search) (AMD). The ongoing eDREAM Phase 2 study (NCT06659549) is evaluating the topical formulation in dry AMD and geographic atrophy patients.
"This highly innovative drug candidate has the potential to significantly impact dry AMD patients who are at risk of going blind," said Céline Olmiere, Director of Théa Open Innovation (search). "Our collaboration with Galimedix supports continued commitment to building a strong cutting-edge and diversified ophthalmological portfolio for eye care specialists and their patients around the world."
Strategic Partnership Framework
The milestone achievement stems from a strategic partnership established in March 2023 between Théa Open Innovation (search) and Galimedix for GAL-101 development and commercialization across Europe, the Americas, the Middle East, and Africa. Under the agreement terms, Galimedix received an upfront technology access fee and remains eligible for additional success-based milestone payments and royalties on net sales.
Théa Open Innovation (search) is fully funding the remaining GAL-101 development in dry AMD and will handle registration and commercialization in ophthalmology, while Galimedix maintains responsibility for conducting mid-stage clinical trials. The partnership also included a direct investment by Théa Open Innovation into Galimedix, demonstrating confidence in the company's broader pipeline including Alzheimer's disease (search) applications.
Preclinical Efficacy Across Multiple Models
Beyond Alzheimer's disease (search) applications, GAL-101 has demonstrated strong efficacy in relevant ophthalmic preclinical models, protecting neuronal retinal cells from toxic damage. The compound is being developed for multiple indications including dry age-related macular degeneration (search), glaucoma (search), and Alzheimer's disease, reflecting the broad therapeutic potential of targeting amyloid beta (search) aggregation across neurodegenerative conditions.
Both oral and eye drop formulations of GAL-101 demonstrated excellent safety and tolerability profiles in Phase 1 testing, with the oral version showing effective blood-brain barrier penetration necessary for central nervous system applications.